Compare BGIN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGIN | BWAY |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.9M | 337.9M |
| IPO Year | 2025 | 2019 |
| Metric | BGIN | BWAY |
|---|---|---|
| Price | $2.98 | $23.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 46.8K | ★ 84.7K |
| Earning Date | 02-22-2026 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $205,457,324.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $71.62 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $2.38 | $7.84 |
| 52 Week High | $6.50 | $23.91 |
| Indicator | BGIN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 80.32 |
| Support Level | N/A | $18.62 |
| Resistance Level | N/A | $23.91 |
| Average True Range (ATR) | 0.00 | 1.10 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 0.00 | 90.68 |
BGIN Blockchain Ltd is operating through its subsidiaries and is engaged in digital asset technology company based in Singapore, Hong Kong and the U.S. with proprietary cryptocurrency-mining technologies and a strategic focus on alternative cryptocurrencies. It design and sell mining machines equipped with proprietary 8nm or 12nm ASIC chips under different series dedicated to the mining of KAS coins, ALPH coins, and RXD coins. The Company operated in two reportable segments, which were the cryptocurrency mining and the sale of mining machines Key revenue is generated from Sale of mining machines. Geographically, It derives key revenue from Hong Kong, China and Vietnam, United States, Singapore, etc.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.